bone targeted agents in metastatic prostate cancer: denosumab, bisphosphonates and radium-223
Published 7 years ago • 2K plays • Length 14:14Download video MP4
Download video MP3
Similar videos
-
13:46
timing and optimization of radium 223 in castration resistant prostate cancer
-
19:01
bone metastases and mortality
-
3:56
bone-targeted therapy for prostate cancer: radium-223
-
3:27
bone supportive therapy and radium-223 for metastatic prostate cancer
-
21:31
choosing a companion drug to radium-223
-
28:49
bone metastases and mortality: can we be doing more?
-
1:25
what combination drugs with radium 223 are best for treating prostate cancer?
-
1:10
dr. dreicer on challenges of radium-223 in prostate cancer
-
3:45
dr. vogelzang reviews radium-223 in metastatic prostate cancer
-
2:14
radium-223 and metastatic prostate cancer
-
4:10
optimal time for prostate cancer bone-targeted therapy
-
15:05
radium-223 in bone-metastatic castration-resistant prostate cancer
-
20:41
update on radiopharmaceuticals: choosing a companion drug to radium-223
-
4:55
bone targeted therapy for metastatic prostate cancer
-
22:16
bone-targeted therapy for prostate cancer
-
3:47
bone-migrated prostate cancer and radium-223 therapy
-
15:33
standard treatment for advanced prostate cancer
-
10:04
update on radiopharmaceuticals: choosing a companion drug to radium-223
-
22:55
update on mechanisms of resistance in castration-resistant prostate cancer